Rafferty Asset Management LLC Boosts Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rafferty Asset Management LLC increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 67.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,454 shares of the biopharmaceutical company's stock after buying an additional 61,464 shares during the period. Rafferty Asset Management LLC owned about 0.23% of Celldex Therapeutics worth $3,853,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CLDX. Barclays PLC boosted its stake in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after purchasing an additional 76,207 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Celldex Therapeutics by 24.4% in the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 4,967 shares during the last quarter. KBC Group NV boosted its position in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares during the last quarter. Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter worth approximately $2,867,000. Finally, Values First Advisors Inc. boosted its position in shares of Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after acquiring an additional 4,837 shares during the last quarter.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.02 during mid-day trading on Friday, hitting $20.35. The company's stock had a trading volume of 477,438 shares, compared to its average volume of 897,536. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The stock's fifty day simple moving average is $18.91 and its two-hundred day simple moving average is $22.38. The firm has a market capitalization of $1.35 billion, a P/E ratio of -7.92 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The business had revenue of $0.70 million during the quarter, compared to analysts' expectations of $1.08 million. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CLDX shares. UBS Group decreased their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Morgan Stanley decreased their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.